For antithrombotic therapy of CKD patients, therapy should relate to eGFR as follows:
<br />
<ol>
	<li>eGFR &gt; 30 mL/min:<br />
		We recommend that such patients receive antithrombotic therapy according to their CHADS<sub>2</sub>  score as detailed in recommendations for patients with normal renal function. (Recommendation Strong, Quality High)
	</li>
	<li>eGFR 15-30 mL/min and not on dialysis:<br />
		We suggest that such patients receive antithrombotic therapy according to their CHADS<sub>2</sub>  score as for patients with normal renal function. The preferred agent for these patients is warfarin. (Recommendation Conditional, Quality Low)<br />
		<b>Values and preferences: </b>This recommendation places a relatively higher value on prevention of ischemic stroke than on bleeding complications associated with antithrombotic therapy, as well as the limited data available for new OACs in CKD patients. No therapy may be appropriate for some patients with eGFR 15-30 mL/min (not on dialysis), with a stronger preference for avoiding bleeding complications than preventing ischemic stroke.
	</li>
	<li>eGFR &lt; 15 mL/min (on dialysis):
		<br/>We suggest that such patients not routinely receive either OAC (Conditional Recommendation, Low-Quality Evidence) or ASA for stroke prevention in AF. (Recommendation Conditional, Quality Low)<br />
		<b>Values and Preferences: </b>Values and preferences. This recommendation places a relatively higher weight on observational data linking warfarin and ASA use with mortality in patients on dialysis, and relatively lower weight on the potential for these agents to prevent ischemic stroke. Therapy with OACs or antiplatelet drugs may be appropriate for some patients with eGFR &lt; 15 mL/min (on dialysis) in whom there is a stronger preference for avoiding ischemic stroke.
	</li>
</ol>